Azenta, Inc. - Common Stock (NQ:AZTA)

37.72 +1.72 (+4.78%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Azenta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment

October 05, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how drug development input...

Via StockStory

Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)

September 30, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Economy

Q2 Rundown: 10x Genomics (NASDAQ:TXG) Vs Other Life Sciences Tools & Services Stocks

September 21, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA)

September 13, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta...

Via StockStory

Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks

September 07, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

3 Healthcare Stocks We Keep Off Our Radar

September 01, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Via StockStory

Winners And Losers Of Q2: Illumina (NASDAQ:ILMN) Vs The Rest Of The Life Sciences Tools & Services Stocks

August 25, 2026

Looking back on life sciences tools & services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Illumina (NASDAQ:ILMN) and...

Via StockStory

Topics Artificial Intelligence

Stocks making big moves yesterday: Funko, Hims & Hers Health, Azenta, Strategy, and RUM Group

August 25, 2026

Check out the companies making headlines yesterday: Funko (NASDAQ:FNKO): Pop culture collectibles manufacturer Funko (NASDAQ:FNKO) rose by 4.9% on Monday aft...

Via StockStory

Topics Artificial Intelligence Credit Cards

Why Azenta (AZTA) Stock Is Down Today

August 24, 2026

What Happened? Shares of life sciences company Azenta (NASDAQ:AZTA) fell 9.1% in the afternoon session after the company announced, in a regulatory filing, t...

Via StockStory

1 Momentum Stock for Long-Term Investors and 2 We Find Risky

August 19, 2026

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...

Via StockStory

Azenta (AZTA) Q3 2026 Earnings Call Transcript ↗

August 11, 2026

Recurring revenue tops 50% as automation investments drive operational progress.

Via The Motley Fool

Topics Earnings

The 5 Most Interesting Analyst Questions From Azenta’s Q2 Earnings Call

August 11, 2026

Azenta’s second quarter showed strong momentum, with results surpassing Wall Street’s expectations for both revenue and earnings. Management attributed this ...

Via StockStory

Topics Earnings

Azenta Q3 Earnings Call Highlights ↗

August 05, 2026

Azenta (NASDAQ:AZTA) reported third-quarter fiscal 2026 revenue that exceeded its outlook, as growth in recurring-revenue businesses and improved Multiomics performance helped offset continued...

Via MarketBeat

Topics Earnings

Azenta (NASDAQ:AZTA) Reports Upbeat Q2 CY2026

August 04, 2026

Life sciences company Azenta (NASDAQ:AZTA) announced better-than-expected revenue in Q2 CY2026, with sales up 12% year on year to $161.2 million. Its non-GAA...

Via StockStory

Azenta (AZTA) Reports Q2: Everything You Need To Know Ahead Of Earnings

August 02, 2026

Life sciences company Azenta (NASDAQ:AZTA) will be reporting results this Tuesday after the bell. Here’s what investors should know. Azenta missed analysts’ ...

Via StockStory

Topics Artificial Intelligence

3 Cash-Burning Stocks Walking a Fine Line

July 31, 2026

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...

Via StockStory

Topics Artificial Intelligence Economy

1 Unprofitable Stock Worth Your Attention and 2 We Avoid

July 23, 2026

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Unprofi...

Via StockStory

Topics Climate Change

3 Unpopular Stocks We Steer Clear Of

July 22, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

3 Reasons to Avoid AZTA and 1 Stock to Buy Instead

June 19, 2026

What a brutal six months it’s been for Azenta. The stock has dropped 30.3% and now trades at $24, rattling many shareholders. This was partly due to its soft...

Via StockStory

3 Cash-Heavy Stocks We Keep Off Our Radar

June 16, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Via StockStory

3 Hyped Up Stocks We Find Risky

June 11, 2026

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

Via StockStory

Topics Economy

3 Small-Cap Stocks with Open Questions

June 10, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

3 High-Flying Stocks Walking a Fine Line

June 08, 2026

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

Via StockStory

Winners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks

May 19, 2026

Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Azenta (NASDAQ:AZTA) a...

Via StockStory

Azenta’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 13, 2026

Azenta’s first quarter was marked by operational challenges and a more cautious demand environment, which contributed to results well below market expectatio...

Via StockStory

Topics Earnings

1 Russell 2000 Stock Worth Your Attention and 2 We Question

May 13, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Via StockStory

Azenta (AZTA) Q2 2026 Earnings Call Transcript ↗

May 06, 2026

Azenta (AZTA) Q2 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Azenta (AZTA) Reports Earnings Tomorrow: What To Expect

May 04, 2026

Life sciences company Azenta (NASDAQ:AZTA) will be announcing earnings results this Wednesday before market hours. Here’s what you need to know. Azenta beat ...

Via StockStory

2 Cash-Heavy Stocks on Our Buy List and 1 We Turn Down

April 23, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

1 Healthcare Stock to Target This Week and 2 We Ignore

April 22, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.